BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...OrbiMed, Lake Bleu Capital and an undisclosed Boston-based firm as joint leading investors. New investors Janchor Partners...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...was led by Lilly Asia Ventures and Lake Bleu Capital. The company’s investors include Vivo Capital, Janchor Partners...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...participated in the IPO.CBC Group acted as the IPO’s cornerstone investor. Also participating were RA Capital, Janchor Partners...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...and Technological Development Zone and Jiashan SDIC invested $50 million in Everest’s series C-1 round. Janchor Partners...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...by Lilly Asia Ventures and Lake Bleu Capital. Also participating were new investors Vivo Capital, Janchor Partners...
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

...17, include Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners...
BioCentury | Nov 16, 2018
Financial News

Alphamab Oncology raises more than $100M series A

...product KN035. Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners...
Items per page:
1 - 7 of 7
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...OrbiMed, Lake Bleu Capital and an undisclosed Boston-based firm as joint leading investors. New investors Janchor Partners...
BioCentury | Nov 10, 2020
Finance

RemeGen’s value surpasses $4B after pricing 2020’s largest biotech IPO

...was led by Lilly Asia Ventures and Lake Bleu Capital. The company’s investors include Vivo Capital, Janchor Partners...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

...participated in the IPO.CBC Group acted as the IPO’s cornerstone investor. Also participating were RA Capital, Janchor Partners...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...and Technological Development Zone and Jiashan SDIC invested $50 million in Everest’s series C-1 round. Janchor Partners...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...by Lilly Asia Ventures and Lake Bleu Capital. Also participating were new investors Vivo Capital, Janchor Partners...
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

...17, include Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners...
BioCentury | Nov 16, 2018
Financial News

Alphamab Oncology raises more than $100M series A

...product KN035. Advantech Capital, PAG, China Venture Capital Fund, OrbiMed Advisors, Heritage Provider Network and Janchor Partners...
Items per page:
1 - 7 of 7